A plain language review of results from the LAURA study: osimertinib after chemoradiotherapy for patients with EGFR-mutated non-small cell lung cancer that cannot be removed by surgery.
OpenAlex 토픽 ·
Lung Cancer Treatments and Mutations
Lung Cancer Diagnosis and Treatment
Lung Cancer Research Studies
APA
Shun Lu, Terufumi Kato, et al. (2026). A plain language review of results from the LAURA study: osimertinib after chemoradiotherapy for patients with EGFR-mutated non-small cell lung cancer that cannot be removed by surgery.. Future oncology (London, England), 1-16. https://doi.org/10.1080/14796694.2026.2652543
MLA
Shun Lu, et al.. "A plain language review of results from the LAURA study: osimertinib after chemoradiotherapy for patients with EGFR-mutated non-small cell lung cancer that cannot be removed by surgery.." Future oncology (London, England), 2026, pp. 1-16.
PMID
42037107
같은 제1저자의 인용 많은 논문 (5)
- Savolitinib plus osimertinib versus chemotherapy for advanced, EGFR mutation-positive, MET-amplified non-small-cell lung cancer in China (SACHI): interim analysis of a multicentre, open-label, phase 3 randomised controlled trial.
- Treatment Patterns and Clinical Outcomes in Unresectable Stage III EGFR-Mutated Non-Small Cell Lung Cancer in China.
- Orbicularis Oculi Toxin Injection for Treating Levator Palpebrae Superioris Weakness: Clinical Effect and Safety in a Cohort Study.
- Complete Remission in BCLC Stage C Hepatocellular Carcinoma Treated with HAIC Combined with PD-1 Inhibitors and Anti-angiogenic Therapy.
- Cancer-Associated Fibroblasts Promote Tumor Immunosuppression in Hepatocellular Carcinoma via the NNMT-ANGPTL4 Axis.